The use of prolonged peripheral neural blockade after lower extremity amputation: the effect on symptoms associated with phantom limb syndrome

B Borghi, M D'Addabbo, PF White… - Anesthesia & …, 2010 - journals.lww.com
B Borghi, M D'Addabbo, PF White, P Gallerani, L Toccaceli, W Raffaeli, A Tognù, N Fabbri…
Anesthesia & Analgesia, 2010journals.lww.com
BACKGROUND: Phantom limb syndrome (PLS) is common after limb amputations, involving
up to 90% of amputees. Although many different therapies have been evaluated, none has
been found to be highly effective. Therefore, we evaluated the efficacy of a prolonged
perineural infusion of a high concentration of local anesthetic solution in preventing PLS.
METHODS: A perineural catheter was placed immediately before or during surgery in 71
patients undergoing lower extremity amputation. A continuous infusion of 0.5% ropivacaine …
BACKGROUND:
Phantom limb syndrome (PLS) is common after limb amputations, involving up to 90% of amputees. Although many different therapies have been evaluated, none has been found to be highly effective. Therefore, we evaluated the efficacy of a prolonged perineural infusion of a high concentration of local anesthetic solution in preventing PLS.
METHODS:
A perineural catheter was placed immediately before or during surgery in 71 patients undergoing lower extremity amputation. A continuous infusion of 0.5% ropivacaine was started intraoperatively at 5 mL/h using an elastomeric (nonelectronic) pump, and continued for 4 to 83 days after surgery. PLS was evaluated on the first postoperative day and then 1, 2, 3, and 4 weeks, and 3, 6, 9, and 12 months after surgery. To evaluate the presence and severity of PLS while the patient was receiving the ropivacaine infusion, it was discontinued for 6 to 12 hours before each assessment period (ie, until the sensation in the extremity returned). The severity of phantom limb and stump pain was assessed using a 5-point verbal rating scale (VRS), with 0= no pain to 4= intolerable pain, and “phantom” sensations were recorded as present or absent. If the VRS score was> 1 or significant phantom sensations were present, the ropivacaine infusion was immediately restarted at 5 mL/h. If the VRS score remained at 0 to 1 and the patient had not experienced phantom sensations for 48 hours, the infusion was permanently discontinued and the catheter was removed.
RESULTS:
Median duration of the local anesthetic infusion was 30 days (95% confidence interval, 25–30 days). On postoperative day 1, 73% of the patients complained of severe-to-intolerable pain (visual analog scale> 2). However, the incidence of severe-to-intolerable phantom limb pain was only 3% at the end of the 12-month evaluation period. At the end of the 12-month period, the percentage of patients with VRS pain scores were 0= 84%, 1= 10%, 2= 3%, 3= 3%, and 4= none. However, phantom limb sensations were present in 39% of patients at the end of the 12-month evaluation period. All patients were able to manage the elastomeric catheter infusion system at home.
CONCLUSION:
Use of a prolonged postoperative perineural infusion of ropivacaine 0.5% seems to be an effective therapy for the treatment of phantom limb pain and sensations after lower extremity amputation.
Lippincott Williams & Wilkins